<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Saarland_3_step"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Saarland/3_step">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Saarland/3_step&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Saarland/3_step&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Saarland/3_step&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Saarland/3_step" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Saarland/3 step</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2014.igem.org</H3><DIV id="wikicontent-container"><DIV><DIV id="menu"><UL><LI><A id="team1" href="https://2014.igem.org/Team:Saarland/Team">Team</A></LI><LI><A id="members" href="https://2014.igem.org/Team:Saarland/Team">Members</A></LI><LI><A id="official" href="https://igem.org/Team.cgi">Official Team Profile</A></LI><LI><A id="press" href="https://2014.igem.org/Team:Saarland/Press">Publicity</A></LI><LI><A id="attribution" href="https://2014.igem.org/Team:Saarland/Attribution">Attributions</A></LI><LI><A id="sponsors" href="https://2014.igem.org/Team:Saarland/Sponsors">Sponsors</A></LI><LI><A id="judging" href="https://2014.igem.org/Team:Saarland/Judging">Judging</A></LI></UL><LI><A id="project3" href="https://2014.igem.org/Team:Saarland/Project">Project</A></LI><LI><A id="project2" href="https://2014.igem.org/Team:Saarland/Project">Overview</A></LI><LI><A id="1." href="https://2014.igem.org/Team:Saarland/anticancergens#thenackedmolerat">Naked mole rat</A></LI><LI><A id="1." href="https://2014.igem.org/Team:Saarland/anticancergens#hyaloronicacid">Hyaluronic acid</A></LI><LI><A id="1." href="https://2014.igem.org/Team:Saarland/anticancergens#HMM-HA">HMM-HA</A></LI><LI><A id="2." href="https://2014.igem.org/Team:Saarland/2_step">B.megaterium </A></LI><LI><A id="2." href="https://2014.igem.org/Team:Saarland/2_step#pathway">Pathway engineering </A></LI><LI><A id="3." href="https://2014.igem.org/Team:Saarland/3_step">Develop Strategy </A></LI><LI><A id="results" href="https://2014.igem.org/Team:Saarland/4_step">Results</A></LI><LI><A id="erg" href="https://2014.igem.org/Team:Saarland/4_step">Results </A></LI><LI><A id="5." href="https://2014.igem.org/Team:Saarland/5_step">Discussion </A></LI><LI><A id="5." href="https://2014.igem.org/Team:Saarland/5_step#outlook">Outlook </A></LI><LI><A id="parts" href="https://2014.igem.org/Team:Saarland/Parts">Parts</A></LI><LI><A id="modeling" href="https://2014.igem.org/Team:Saarland/Modeling">Modelling</A></LI><LI><A id="rpg" href="https://2014.igem.org/Team:Saarland/rpg">Human Resources</A></LI><LI><A id="notebook" href="https://2014.igem.org/Team:Saarland/Labbook">Notebook</A></LI><LI><A id="labbook" href="https://2014.igem.org/Team:Saarland/Labbook">Lab journal</A></LI><LI><A id="Methods" href="https://2014.igem.org/Team:Saarland/Methods">Methods</A></LI><LI><A id="Materials" href="https://2014.igem.org/Team:Saarland/Materials">Materials</A></LI><LI><A id="safety" href="https://2014.igem.org/Team:Saarland/Safety">Safety </A></LI></DIV></DIV></DIV><DIV id="wikicontent-container"><DIV id="wikicontent"><H1><SPAN class="mw-headline" id="Step_3:_Develop_Strategy">Step 3: Develop Strategy  </SPAN></H1><H3><SPAN class="mw-headline" id="In_this_section_we_will_discuss_the_strategy_and_major_aims_of_our_project.">In this section we will discuss the strategy and major aims of our project.</SPAN></H3><P>The first step of our project will be the preparation of the naked mole rat hyaluronan synthase gene (<I>has</I>2), as well as the endogenous <I>B. megaterium</I> gene coding for UDP-glucose 6-dehydrogenase (UDP-GlcDH), which catalyses the formation of the precursor molecule UDP-D-glucuronate. For the cloning process of the <I>UDP-glc</I>DH gene, we are going to extract the genomic DNA of <I>B. megaterium</I> cells and subsequently amplify the gene directly from the isolated genomic DNA. In the case of the <I>has</I>2 gene this approach is not possible, because it is necessary to adapt the codon usage of the mammalian<I> has</I>2 gene to ensure an efficient expression in <I>B. megaterium</I>. For that reason we are going to adapt the codon usage of <I>has2 in silico</I> with the online codon adaption tool <A href="http://www.jcat.de/" class="external text" rel="nofollow">JCat</A>. Afterwards the gene will be synthesised by <A href="http://www.eurofinsgenomics.eu/" class="external text" rel="nofollow">Eurofins</A>.
</P><P>The two genes will be cloned into the shuttle plasmid pSMF2.1 which allows on the one hand the efficient amplification of plasmid DNA in high copy numbers in <I>E. coli</I> cells. On the other hand pSMF2.1 is optimised for expression of recombinant proteins in <I>B. megaterium</I>. For the integration of <I>has</I>2 and <I>UDP-glc</I>DH into the pSMF2.1 plasmid, the genes will be amplified with concomitant addition of appropriate restriction sites. For the cloning procedure of the <I>has</I>2 gene the restriction enzymes <I>Mlu</I>Ⅰ and <I>Sac</I>Ⅰ will be used, while the <I>UDP-glc</I>DH gene will be integrated by use of  <I>Sac</I>Ⅰ and <I>Sph</I>Ⅰ.
</P><P>In the next step two pSMF2.1 constructs will be designed. The first one containing only the <I>has</I>2 gene with adapted codon usage and the second one containing the <I>has</I>2 gene as well as the endogenous <I>UDP-glc</I>DH gene. Each gene will be integrated with its own ribosomal binding site (RBS) to enable an efficient expression. In figure 1 the planned cloning procedure is schematically shown.</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:542px;"><DIV class="thumbcaption"><B> Figure 1:</B> Insertion of hyaluronan synthase (<I>has</I>2) in the pSMF2.1 plasmid.</DIV></DIV></DIV></DIV><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:542px;"><DIV class="thumbcaption"><B> Figure 2:</B> Insertion of UDP-glucose-dehydrogenase (<I>UDP-glc</I>DH) in the pSMF2.1-<I>has</I>2 plasmid.</DIV></DIV></DIV></DIV><P>
In the next step of our project we are going to transform <I>B. megaterium</I> cells with the created plasmid constructs to finally express the proteins and produce high molecular mass hyaluronic acid (HMM-HA). As expression host we are going to employ the <I>B. megaterium</I> strain MS941, which was derived from the naturally occurring strain DSM319 by knockout of the neutral protease gene <I>npr</I>M (Wittchen <I>et al</I>., 1995) and therefore well suited for protein expression (Stammen <I>et al</I>., 2007).
</P><P>Before transformation of MS941 cells the bacterial cell wall has to be degraded. Therefore lysozyme will be used which splits the β 1,4-glycosidic bond between N-acetylmuramic acid and N-acetyl-D-glucosamine, and thereby leads to the formation of competent protoplasts. Afterwards the lysozyme will be removed and the transformation will be carried out. Figure 3 schematically shows the transformation of <I>B. megaterium</I> cells of the strain MS941 with the plasmid pSMF2.1-<I>has</I>2-<I>UDP-glc</I>DH.
</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:542px;"><DIV class="thumbcaption"><B> Figure 3:</B> Transformation of the pSMF2.1-<I>has</I>2-<I>UDP-glc</I>DH plasmid in <I> B.megaterium</I>.</DIV></DIV></DIV></DIV><P>After the successful cloning and transformation procedure the transformed MS941 cells will be incubated in baffled flasks in shakers. For the induction of the protein expression xylose will be added in 0.5 % concentration (w/v) which will lead to an inhibition of the xylose repressor (XylR) and therefore to an activation of the promotor.
</P><P>To verify the existence of active Has2 we intend to examine the protein expression, as well as the HMM-HA production. For the protein detection we are going to prepare an SDS-Gel in which the expressed Has protein (Has2) should be detectable after staining with Coomassie Brilliant Blue. Furthermore we are going to examine the protein localisation by expressing an GFP tagged variant of Has2, which can be visualised by fluorescence microscopy as well as by Western Blot analysis with an anti-GFP antibody.
</P><P>For the HMM-HA detection and quantification we are going to measure the viscosity of the media 24 h and 48 h after the induction of protein expression. The viscosity should drastically increase, when HMM-HA will be synthesised, because the molecule is able to bind large amounts of water. For the measurement of viscosity we are going to use the method of rheology.
</P><P>After successful detection of the HMM-HA we want to purify it following the protocol of Widner <I>et al</I>. (2005). Additionally we are going to verify the high molecular mass of the produced HMM-HA by pulse field gel electrophoresis as described by Tian <I>et al</I>. (2013). Finally we intend to test the effects of the purified HMM-HA on different human cancer cell lines. In particular we are going to examine the CD44 receptor dependant effects and signal cascades in human skin cancer cell lines by proliferation and cytotoxicity assays.
</P><P>Lastly we are going to improve the purification protocols, as well as the recombinant HMM-HA production by varying different external parameters like flask form, temperature conditions during incubation, incubation time and shaking speed.
</P><P><A href="https://2014.igem.org/Team:Saarland/2_step"><B> Previous Step </B></A></P><DIV style="margin-left:765px;margin-top:-73px;"><A href="https://2014.igem.org/Team:Saarland/4_step"><B> Next Step</B></A></DIV><H3><SPAN class="mw-headline" id="References">References</SPAN></H3><P><B>Stammen</B>, S., Müller, B.K., Korneli, C., Biedendieck, R., Gamer, M., Franco-Lara, E., and Jahn, D. (2010). High-Yield Intra- and Extracellular Protein Production Using Bacillus megaterium. Appl. Environ. Microbiol. 76, 4037–4046.<B>Tian</B>, X., Azpurua, J., Hine, C., Vaidya, A., Myakishev-Rempel, M., Ablaeva, J., Mao, Z., Nevo, E., Gorbunova, V., and Seluanov, A. (2013). High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 499, 346–349.<B>Widner</B>, B., Behr, R., Dollen, S.V., Tang, M., Heu, T., Sloma, A., Sternberg, D., DeAngelis, P.L., Weigel, P.H., and Brown, S. (2005). Hyaluronic Acid Production in Bacillus subtilis. Appl. Environ. Microbiol. 71, 3747–3752.<B>Wittchen</B>, K.D., and Meinhardt, F. (1995). Inactivation of the major extracellular protease from Bacillus megaterium DSM319 by gene replacement. Appl. Microbiol. Biotechnol. 42, 871–877.</P></DIV></DIV><DIV id="social-footer"><DIV><H4><A href="https://2014.igem.org/Team:Saarland/Impressum">Impressum/Copyright</A></H4></DIV></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2014.igem.org/Team:Saarland/3_step">http://2014.igem.org/Team:Saarland/3_step</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Saarland/3_step" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Saarland/3_step" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Saarland/3_step&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Saarland/3_step&amp;oldid=316131" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2014.igem.org:Privacy_policy" title="2014.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2014.igem.org:General_disclaimer" title="2014.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>